Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide: a re-look.

J K Grover1, V Vats, R Gopalakrishna

  • 1Department of Pharmacology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.

The National Medical Journal of India
|September 18, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disseminated Phaeohyphomycosis in a Patient With CARD 9 Mutation.

International journal of dermatology·2026
Same author

Clinically suspected granulomatous skin lesions on the face: A prospective clinico-pathological correlation study of 77 cases.

Indian journal of dermatology, venereology and leprology·2026
Same author

Assessment of vitiligo in clinical practice: a cross-sectional survey among experts.

The Journal of dermatological treatment·2025
Same author

A prospective observational study of the dermoscopic findings of nonsegmental vitiligo in different stages of evolution.

Clinical and experimental dermatology·2025
Same author

Paroxysmal Nocturnal Hemoglobinuria Associated Cutaneous Thrombosis: A Case Report.

Indian dermatology online journal·2025
Same author

Do we need a new name for early mycosis fungoides to reduce fear and improve patient care?

Indian journal of dermatology, venereology and leprology·2025
Same journal

Robotic surgery: The beginning and the journey so far.

The National medical journal of India·2026
Same journal

Workplace violence against junior doctors in a tertiary care hospital in Manipur and coping strategies: A mixed-method study.

The National medical journal of India·2026
Same journal

Digital library of court cases of the main hospital of the All India Institute of Medical Sciences, New Delhi: An innovation to deal with hospital litigations.

The National medical journal of India·2026
Same journal

Benidipine-induced lichenoid drug eruption.

The National medical journal of India·2026
Same journal

Aortoplasty balloon catheter for aortic occlusion in patients with massive truncal haemorrhage: A cadaveric study.

The National medical journal of India·2026
Same journal

Cutaneous tuberculosis: Prevention, management, challenges and future perspectives.

The National medical journal of India·2026
See all related articles

Thalidomide, initially a sedative, is now a preferred treatment for erythema nodosum leprosum (ENL). Its anti-inflammatory properties also benefit other conditions like lupus and graft-versus-host disease.

Area of Science:

  • Immunology
  • Pharmacology
  • Dermatology

Background:

  • Thalidomide was initially marketed as a sedative but was withdrawn due to severe teratogenic effects.
  • A serendipitous discovery highlighted its potential in treating erythema nodosum leprosum (ENL).

Purpose of the Study:

  • To review established studies on thalidomide's efficacy in various medical conditions.
  • To evaluate thalidomide's therapeutic role beyond ENL, considering its anti-inflammatory and immunomodulatory properties.

Main Methods:

  • Inclusion of only well-defined studies substantiating thalidomide's efficacy.
  • Review of clinical trials and observational data on thalidomide's use.

Main Results:

  • Thalidomide is the drug of choice for ENL, recommended by the WHO and approved by the FDA.

Related Experiment Videos

  • Demonstrated efficacy in dermatological conditions such as systemic lupus erythematosus, discoid lupus erythematosus, actinic prurigo, and prurigo nodularis.
  • Therapeutic applications identified in graft-versus-host disease, AIDS-related wasting, aphthous ulcers, and Kaposi's sarcoma.

    • Conclusions:

    • Thalidomide is a safe and effective treatment for ENL and several other conditions when used correctly.
    • Its use is recommended for other conditions primarily when standard therapies fail.
    • Thalidomide is not indicated as an immunosuppressant in solid organ transplantation but has a role in graft-versus-host disease.